ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IMMUCELL CORP /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.51−0.24 (-2.23%)
Close on Oct 19, 2026
- Market cap
- $96.58M
- P/E (TTM)
- 131.4
- Dividend yield
- –
IMMUCELL CORP /DE/ revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment, Scours [Member] | $30.44M | $29.73M | $27.45M | $27.58M | $28.09M | – | $26.31M | – | – | – | – | – | 99.2% | +8.4% |
| Corporate Segment, Mastitis [Member] | $236.20K | $207.22K | $196.39K | $185.49K | $184.21K | – | $178.92K | – | – | – | – | – | 0.8% | +28.2% |
| Scours [Member] | – | – | – | – | $28.09M | $27.12M | $26.31M | $23.64M | $23.05M | $21.10M | $17.29M | $16.13M | – | – |
| Mastitis [Member] | – | – | – | – | $184.21K | $180.67K | $178.92K | $195.57K | $171.78K | $179.38K | $177.74K | $158.48K | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment, Scours [Member] | $7.82M | $8.73M | $7.89M | $8.01M | $7.42M | – | $4.78M | – | – | – | – | – | +5.4% |
| Corporate Segment, Mastitis [Member] | $448.18K | -$2.38M | -$2.92M | -$2.91M | -$3.11M | – | -$4.04M | – | – | – | – | – | -114.4% |
| Other [Member] | – | – | – | – | -$2.58M | -$2.47M | -$2.38M | -$2.32M | -$2.31M | -$2.24M | -$2.28M | -$2.32M | – |
| Scours [Member] | – | – | – | – | $7.42M | $5.65M | $4.78M | $3.41M | $3.21M | $3.36M | $1.38M | $911.53K | – |
| Mastitis [Member] | – | – | – | – | -$3.11M | -$3.40M | -$4.04M | -$4.35M | -$4.77M | -$4.92M | -$4.85M | -$4.97M | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Defense product line [Member] | – | – | – | – | $28.09M | $27.12M | $26.31M | $23.64M | $23.05M | $21.10M | $17.29M | $16.13M | – | – |
| Other animal health [Member] | – | – | – | – | $184.21K | $180.67K | $178.92K | $195.57K | $171.78K | $179.38K | $177.74K | $158.48K | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other [Member] | – | – | – | – | $4.56M | $3.57M | $3.60M | $2.61M | $2.29M | $1.99M | $1.52M | $1.42M | – | – |
| United States | – | – | – | – | $23.71M | $23.73M | $22.89M | $21.22M | $20.93M | $19.29M | $15.95M | $14.86M | – | – |
From the segment and revenue-disaggregation notes of Immucell's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.